PMID: 11925293Apr 2, 2002Paper

Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia

The American Journal of Psychiatry
Michael J SernyakRobert A Rosenheck

Abstract

The development of both type I and type II diabetes after initiation of some atypical neuroleptics has been reported, primarily in studies involving small series of patients. This study used administrative data from a large national sample of patients with a diagnosis of schizophrenia to compare the prevalence of diabetes mellitus in patients receiving prescriptions for atypical and typical neuroleptics. All outpatients with schizophrenia treated with typical and atypical neuroleptics over 4 months in 1999 in the Veterans Health Administration of the Department of Veterans Affairs (VA) were included in this study. Patients treated with atypical neuroleptics were those who received prescriptions for clozapine, olanzapine, risperidone, or quetiapine. Patients with a diagnosis of diabetes were also identified by using ICD-9 codes in VA administrative databases. The prevalence of diabetes mellitus across age groups and among patients receiving prescriptions for different atypical neuroleptics was examined with multiple logistic regression. A total of 38,632 patients were included in the study: 15,984 (41.4%) received typical neuroleptics and 22,648 (58.6%) received any atypical neuroleptic (1,207 [5.3%] received clozapine; 10,970 [...Continue Reading

Citations

Jan 7, 2003·Pharmacoepidemiology and Drug Safety
Aug 1, 2007·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·Paul E HarrisAntonella Maffei
Jun 15, 2006·Der Nervenarzt·T Attarbaschi, S Kasper
Mar 21, 2007·Social Psychiatry and Psychiatric Epidemiology·Christiane RoickMatthias C Angermeyer
Jul 3, 2007·Social Psychiatry and Psychiatric Epidemiology·Carolyn HarleyWilliam Carson
Jun 25, 2005·Community Mental Health Journal·Linda ChafetzJohn Nickens
Feb 7, 2004·Current Diabetes Reports·Roopa Sathyaprakash, Robert R Henry
Jul 20, 2002·Current Psychiatry Reports·Jeremy A Sable, Dilip V Jeste
May 4, 2005·Progress in Neuro-psychopharmacology & Biological Psychiatry·Chi-Fa HungPao-Yen Lin
Mar 26, 2003·Journal of Psychiatric Research·Ulrich ZimmermannThomas Pollmächer
Dec 23, 2003·Progress in Neuro-psychopharmacology & Biological Psychiatry·Frank-Gerald Pajonk
Mar 26, 2003·Journal of Clinical Epidemiology·John B BuseLois Jovanovic
Aug 21, 2003·European Psychiatry : the Journal of the Association of European Psychiatrists·Ann M Mortimer
Jan 7, 2004·Journal of the American Medical Directors Association·Peter D FeldmanAlan Breier
Jan 26, 2010·International Psychogeriatrics·Serge GauthierConstantine Lyketsos
Feb 5, 2013·CNS Spectrums·Donatella MarazzitiLiliana Dell'Osso
Oct 30, 2008·Nature Clinical Practice. Endocrinology & Metabolism·Samuel Dagogo-Jack
Aug 23, 2007·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Julia SacherSiegfried Kasper
Sep 21, 2005·The New England Journal of Medicine·Robert Freedman
Oct 31, 2003·The New England Journal of Medicine·Robert Freedman
Sep 27, 2003·Diabetes Technology & Therapeutics·Clifford Clark, Mark R Burge
Jan 22, 2005·Journal of Child and Adolescent Psychopharmacology·Helen E CourvoisieMark A Riddle
Mar 29, 2008·Metabolic Syndrome and Related Disorders·Trino BaptistaMaritza Martinez
May 2, 2007·Schizophrenia Bulletin·Mark OlfsonHaya Ascher-Svanum
Jul 20, 2007·Schizophrenia Bulletin·R A RosenheckMichael Sernyak
Jan 1, 2008·Schizophrenia Bulletin·Othman SentissiMarie-France Poirier
Apr 28, 2006·Current Opinion in Psychiatry·Maria A Rettenbacher
May 29, 2004·Clinical Nurse Specialist CNS·Barbara Harrison
Jan 25, 2003·Journal of the American Academy of Child and Adolescent Psychiatry·Sarah B SchurPeter S Jensen
Apr 23, 2004·International Clinical Psychopharmacology·Takashi TogoKenji Kosaka
Apr 27, 2004·International Clinical Psychopharmacology·Jonathan M MeyerChristine Y Moutier
Sep 17, 2003·American Journal of Therapeutics·Sanjay GuptaPeggy Keller
Jan 12, 2005·Journal of Clinical Psychopharmacology·Bruce L LambertWilliam Carson
Aug 28, 2003·Southern Medical Journal·Sirpa A Tavakoli, Maria S Arguisola
Sep 15, 2010·Current Opinion in Psychiatry·Thomas J Raedler
Apr 7, 2007·International Clinical Psychopharmacology·Joseph PeuskensUNKNOWN SOLIANOL Study Group

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Autoimmune Diabetes & Tolerance

Patients with type I diabetes lack insulin-producing beta cells due to the loss of immunological tolerance and autoimmune disease. Discover the latest research on targeting tolerance to prevent diabetes.